Join

Compare · MIRM vs NVS

MIRM vs NVS

Side-by-side comparison of Mirum Pharmaceuticals Inc. (MIRM) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MIRM and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $284.62B, about 49.9x MIRM ($5.70B).
  • Over the past year, MIRM is up 94.7% and NVS is up 24.7% - MIRM leads by 70.0 points.
  • MIRM has hit the wire 14 times in the past 4 weeks while NVS has been quiet.
  • Both have 25 recent analyst ratings on file.
PerformanceMIRM+94.69%NVS+24.66%
2025-06-09+0.00%2026-06-08
MetricMIRMNVS
Company
Mirum Pharmaceuticals Inc.
Novartis AG
Price
$91.66-2.00%
$147.14-1.29%
Market cap
$5.70B
$284.62B
1M return
-10.99%
+1.15%
1Y return
+94.69%
+24.66%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2019
News (4w)
14
0
Recent ratings
25
25
MIRM

Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest MIRM

Latest NVS